The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

New Strategy Shifts Pfizer Away from New Hep C Drug

Back to News Homepage

Next

Upcoming Hepatitis C Trial

BiolineRX Gains Momentum for Pre-Clinical HCV Drug

March 15, 2013

Print this page

Joint investment for BL-8030 is in advanced negotiation, potentially expediting the development of BiolineRX’s experimental Hepatitis C drug.

BiolineRX in advanced talks on hepatitis C drug development deal

BL-8030 is an orally-available small molecule to suppress the substance thought critical for the replication of the hepatitis virus.

12 March 13, Gali Wienreb

BiolineRX Ltd. (Nasdaq: BLRX); TASE:BLRX) today announced in its financial report for 2012 that it is advanced talks on a joint development agreement for BL-8030 for the treatment of hepatitis C, which could substantially expedite the development process.

Analysis of the remarks by BiolineRX CEO Dr. Kinneret Savitsky implies that the deal is not yet a material commercialization agreement, but an earlier stage deal involving joint investment in development of the drug. Nonetheless, this is an interesting development for the product, which is still in the preclinical stage. There have been other development collaboration agreements signed for hepatitis C drugs in the preclinical stage.

Continue reading this entire article:
http://www.globes.co.il/serveen/globes/docview.asp?did=1000829401

No Comments - be the first!
Share
Share

Previous

New Strategy Shifts Pfizer Away from New Hep C Drug

Back to News Homepage

Next

Upcoming Hepatitis C Trial

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.